A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis

作者：Rebecca Cosgriff, Susannah Ahern, Scott Cameron Bell, Keith Graham Brownlee, Pierre‐Régis Burgel, Cass Byrnes, Harriet Corvol, Stephanie Y. Cheng, Alexander A. Elbert, Albert Faro, Christopher Hooper Goss, Vincent A. M. Gulmans, Bruce C. Marshall, Edward F. McKone, Peter Gordon Middleton, Rasa Ruseckaite, Anne L. Stephenson, S.B. Carr, David W. Reid, Peter A. B. Wark, Géraldine Daneau, V. Boussaud, Graziella Brinchault, Emmanuelle Coirier-Duet, J.‐C. Dubus, Dominique Grenet, Sandra de Miranda, L. Beaumont, Reem A. Kanaan, Muriel Lauraens, Clémence Martin, Marie Mittaine, Anne Prévötat, Martine Reynaud‐Gaubert, Isabelle Sermet‐Gaudelus, Aurélie Tatopoulos, Lutz Nährlich, Barry J. Plant, Cedric Gunaratnam, Abaigeal D. Jackson, Karin M. de Winter-de Groot, Bart Luijk, Geertjan Wesseling, Mark Ivan Allenby, Jamie M Duckers, Elaine Gunn, Andrew M. Jones, Robert Ian Ketchell, Susan L. Madge, Anirban Maitra, Ghulam Mujtaba, Helen Rodgers, Nadia Shafi, Nicholas J. Simmonds, Kevin W Southern, Danie Watson, Samar Rizvi, J Seguin, J. Garbarz, Kristen Rosamilia, Maria N. Berdella, Jerry A. Nick, R. Belkin, Diana Gilmore, Kim McBennett, Rita Padoan, Marco Salvatore · 发表于：Journal of Cystic Fibrosis · 年份：2020 · DOI：10.1016/j.jcf.2020.04.012 · 被引用次数：141 · 研究领域：Cystic Fibrosis Research Advances、SARS-CoV-2 detection and testing、COVID-19 Clinical Research Studies

Information is lacking on the clinical impact of the novel coronavirus, SARS-CoV-2, on people with cystic fibrosis (CF). Our aim was to characterise SARS-CoV-2 infection in people with cystic fibrosis. METHODS: Anonymised data submitted by each participating country to their National CF Registry was reported using a standardised template, then collated and summarised. RESULTS: 40 cases have been reported across 8 countries. Of the 40 cases, 31 (78%) were symptomatic for SARS-CoV-2 at presentation, with 24 (60%) having a fever. 70% have recovered, 30% remain unresolved at time of reporting, and no deaths have been submitted. CONCLUSIONS: This early report shows good recovery from SARS-CoV-2 in this heterogeneous CF cohort. The disease course does not seem to differ from the general population, but the current numbers are too small to draw firm conclusions and people with CF should continue to strictly follow public health advice to protect themselves from infection.